Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis

Figure 2

Effect of aprepitant or fasudil treatment on heart size in viral-myocarditis. Heart-to-body weight ratios of EMCV uninfected mice and infected mice, with and without aprepitant or fasudil treatment. Results are expressed as the mean ± SD of 2 separate experiments (Heart-to-body weight ratios (expressed in terms of milligrams of heart weight to milligrams of total body weight), of, , uninfected versus infected, †, infected, with versus without aprepitant pretreatment, ‡, infected, with versus without aprepitant posttreatment and, δ, infected, with versus without fasudil posttreatment, mice (all , ANOVA) ()).